BRIEF published on 09/11/2024 at 08:35, 6 months 22 days ago BiVictriX Therapeutics plc Shares Now Trading on JP Jenkins JP Jenkins Share Trading Cancer Therapeutics BiVictriX Bi-Cygni ADCs
BRIEF published on 09/11/2024 at 08:35, 6 months 22 days ago Les actions de BiVictriX Therapeutics plc sont désormais négociées sur JP Jenkins Négociation D'actions J.P. Jenkins BiVictriX Thérapies Contre Le Cancer ADC Bi-Cygni
PRESS RELEASE published on 09/11/2024 at 08:30, 6 months 22 days ago BiVictriX Therapeutics plc Shares now trading on JP Jenkins BiVictriX Therapeutics plc shares are now trading on JP Jenkins, providing a platform for shareholders to buy and sell equity. BiVictriX focuses on developing innovative cancer therapeutics JP Jenkins Shares Trading Shareholder Engagement Cancer Therapeutics BiVictriX Therapeutics Plc
Published on 04/04/2025 at 00:00, 23 minutes ago Onco-Innovations' Inka Health Completes Analytical Work for AstraZeneca Canada, Advancing Pharmaceutical Analytics and Leading to Key Studies at ISPOR 2025
Published on 04/03/2025 at 15:05, 9 hours 18 minutes ago Snowline Gold Closes Fully Subscribed C$20 Million Financing Of Flow-Through Shares
Published on 04/03/2025 at 15:00, 9 hours 23 minutes ago Kingstone Insurance Partners with Kyber Technologies Inc.
Published on 04/03/2025 at 15:00, 9 hours 23 minutes ago UniDoc Announces Debt Settlement and Renews Marketing Engagement
Published on 04/03/2025 at 15:00, 9 hours 23 minutes ago Xebra Brands’ Largest Shareholder Increases Stake as Company Explores Landmark Agricultural Agreement in Mexico
Published on 04/03/2025 at 18:46, 5 hours 36 minutes ago Monthly disclosure of the total number of shares and voting rights - March 2025
Published on 04/03/2025 at 18:46, 5 hours 36 minutes ago Déclaration mensuelle des actions et droits de vote – Mars 2025
Published on 04/03/2025 at 18:00, 6 hours 23 minutes ago LDC : Chiffre d'affaires 2024-2025 : 6,3 milliards d’euros, au-delà des objectifs.
